Article Page

Abstract

Using von Neumann’s continuous geometry in conjunction with A. Connes’ noncommutative geometry an exact mathematical-topological picture of quantum spacetime is developed ab initio. The final result coincides with the general conclusion of E-infinity theory and previous results obtained in the realm of high energy physics. In particular it is concluded that the quantum particle and the quantum wave spans quantum spacetime and conversely quantum particles and waves mutates from quantum spacetime of a novel drug-target combined Bayesian formulation for the Rational Discovery of a Specific FWCS/LQIHFTLIXAFCCEN Peptide mimetic Pharmacophoric Inhibitor against p38a MAPK at HNSCC Allosteric-Sites.

Keywords

E-Infinity, Quantum Spacetime, Noncommutative Geometry, Fractals, Transfinite Set Theory, Von Neumann Continuous Geometry, Cantor Sets, Fusion Algebra, Zero Point Energy, Vacuum Fluctuation, Quantum Field Theory, Casimir Effect, Dark Energy, Exact Mathematical Picture; Quantum Spacetime;Hypercomplex Extensions; Quantum Theory; novel drug-target; combined Bayesian formulation; Rational Discovery; FWCS/LQIHFTLIXAFCCEN; Peptide mimetic; Pharmacophoric Inhibitor; p38a MAPK; HNSCC Allosteric-Sites;

Article Type

Research Article – Abstract

Publication history

Received: Sep 20, 2017
Accepted: Sep 25, 2017
Published: Oct 01, 2017

Citation

Grigoriadis Ioannis, Grigoriadis George, Grigoriadis Nikolaos, George Galazios (2017) An Exact Mathematical Picture of Quantum SpacetimeOn Hypercomplex Extensions of Quantum TheoryA novel drug-target combined Bayesian formulation for the Rational Discovery of a Specific FWCS/LQIHFTLIXAFCCEN Peptide mimetic Pharmacophoric Inhibitor against p38a MAPK at HNSCC Allosteric-Sites.

Authors Info

Grigoriadis Nikolaos
Department of IT Computer Aided Personalized Myoncotherapy, Cartigenea-Cardiogenea, Neurogenea-Cellgenea, Cordigenea-HyperoligandorolTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

Grigoriadis Ioannis
Department of Computer Drug Discovery Science, BiogenetoligandorolTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

Grigoriadis George
Department of Stem Cell Bank and ViroGeneaTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

George Galazios
Professor of Obstetrics and Gynecology,
Democritus University of Thrace,
Komotini, Greece;

E-mail: biogeneadrug@gmail.com

File not available